Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction.

ABSTRACT: Cardiovascular toxicity in the form of cardiac dysfunction continues to be an obstacle for patients with cancer. Survival and quality of life of cancer survivors are frequently affected by increased incidence of cardiovascular disease. The involvement of the cardiovascular system by primary or secondary malignancies, as well as its dysfunction secondary to the administration of antineoplastics, has led to the development of a new discipline called Cardio-Oncology, an exciting cardiology subspecialty with more questions than answers and as a result an enormous opportunity for research in the field. Multidisciplinary efforts have been focused on the prevention, diagnosis, and treatment of cancer therapeutics-related cardiovascular dysfunction (CTRCD). This review article will focus on the ea

SUBMITTER: Manrique CR 

PROVIDER: S-EPMC5392033 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature